Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of Pemziviptadil (PB1046), a Sustained-Release VIP (Vasoactive Intestinal Peptide) ANalogue, in Hospitalized COVID-19 Patients at HiGh Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04433546
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:54.229207+00:00
Published At
2020-12-11T00:00:00+00:00
Record Updated At
2020-12-11
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Respiratory Distress Syndrome", "Coronavirus", "Hypoxic Respiratory Failure", "Hypoxemic Respiratory Failure", "Respiratory Complication", "Respiratory Insufficiency", "Cardiac Dysfunction", "Pneumonia", "Pulmonary Edema", "Pulmonary Inflammation", "Respiratory Failure", "Cytokine Storm", "COVID 19", "SARS-CoV-2", "Cardiac Event", "Cardiac Complication", "Cardiac Failure", "Cardiac Infarct"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-12-11"
protocolSection.identificationModule.nctId
"NCT04433546"
protocolSection.identificationModule.officialTitle
"A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of Pemziviptadil (PB1046), a Sustained-Release VIP (Vasoactive Intestinal Peptide) ANalogue, in Hospitalized COVID-19 Patients at HiGh Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study)"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Acute Respiratory Distress Syndrome (protocolSection.conditionsModule.conditions)
  • Coronavirus (protocolSection.conditionsModule.conditions)
  • Hypoxic Respiratory Failure (protocolSection.conditionsModule.conditions)
  • Hypoxemic Respiratory Failure (protocolSection.conditionsModule.conditions)
  • Respiratory Complication (protocolSection.conditionsModule.conditions)
  • Respiratory Insufficiency (protocolSection.conditionsModule.conditions)
  • Cardiac Dysfunction (protocolSection.conditionsModule.conditions)
  • Pneumonia (protocolSection.conditionsModule.conditions)
  • Pulmonary Edema (protocolSection.conditionsModule.conditions)
  • Pulmonary Inflammation (protocolSection.conditionsModule.conditions)
  • Respiratory Failure (protocolSection.conditionsModule.conditions)
  • Cytokine Storm (protocolSection.conditionsModule.conditions)
  • COVID 19 (protocolSection.conditionsModule.conditions)
  • SARS-CoV-2 (protocolSection.conditionsModule.conditions)
  • Cardiac Event (protocolSection.conditionsModule.conditions)
  • Cardiac Complication (protocolSection.conditionsModule.conditions)
  • Cardiac Failure (protocolSection.conditionsModule.conditions)
  • Cardiac Infarct (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.